News

TB R&D Update: Researchers at EPFL create organization to help bring promising new antibiotic, ‘PBTZ169’, to market

Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575

A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis by researchers at EPFL and the Bach Institute in Moscow. In a paper published in EMBO Molecular Medicine, researchers showed that PBTZ169 inhibited DprE1, an essential enzyme in cell wall biosynthesis. Furthermore, combination treatment of PBTZ169 with BDQ and pyrazinamide was shown to be more efficacious than the standard treatment for tuberculosis in a mouse model.

Following the publication of PBTZ169, researchers set up Innovative Medicines for Tuberculosis (iM4TB), an organization whose mission is to help usher the new antibiotic to market. Clinical trials of PBTZ169 are scheduled to begin in 2015. For more information on iM4TB visit http://im4tb.org/.

Additional Coverage and Links

EPFL sets up foundation to release antibiotic for tuberculosis

http://im4tb.org/

http://www.newtbdrugs.org/project.php?id=145554

Additional TB R&D News

Time-Dependent Diaryl Ether Inhibitors of InhA: Structure–Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy

More News
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...